These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 19212679)
1. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Freeburg EM; Goyeneche AA; Telleria CM Int J Oncol; 2009 Mar; 34(3):743-55. PubMed ID: 19212679 [TBL] [Abstract][Full Text] [Related]
2. Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin. Kapperman HE; Goyeneche AA; Telleria CM Cancer Cell Int; 2018; 18():185. PubMed ID: 30479564 [TBL] [Abstract][Full Text] [Related]
4. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells]. Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028 [TBL] [Abstract][Full Text] [Related]
5. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Qamar L; Davis R; Anwar A; Behbakht K Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662 [TBL] [Abstract][Full Text] [Related]
6. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Freeburg EM; Goyeneche AA; Seidel EE; Telleria CM Cancer Cell Int; 2009 Feb; 9():4. PubMed ID: 19222856 [TBL] [Abstract][Full Text] [Related]
7. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells. Dasari VR; Carey DJ; Gogoi R BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422 [TBL] [Abstract][Full Text] [Related]
8. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413 [TBL] [Abstract][Full Text] [Related]
9. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Goyeneche AA; Carón RW; Telleria CM Clin Cancer Res; 2007 Jun; 13(11):3370-9. PubMed ID: 17545545 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522 [TBL] [Abstract][Full Text] [Related]
11. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity. Gamarra-Luques CD; Hapon MB; Goyeneche AA; Telleria CM J Ovarian Res; 2014; 7():45. PubMed ID: 24795781 [TBL] [Abstract][Full Text] [Related]
12. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells]. Liu GY; Qu QX; Mi RR; Qi J Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754 [TBL] [Abstract][Full Text] [Related]
13. The Effect of Calycosin-7-O-β-D-Glucoside and its Synergistic Augmentation of Cisplatin-induced Apoptosis in SK-OV-3 Cells. Huang JZ; Li LL; Tan XY; Wu ZY; Chen DW; Luo X Curr Pharm Des; 2022; 28(26):2161-2166. PubMed ID: 35702792 [TBL] [Abstract][Full Text] [Related]
14. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. Tieszen CR; Goyeneche AA; Brandhagen BN; Ortbahn CT; Telleria CM BMC Cancer; 2011 May; 11():207. PubMed ID: 21619605 [TBL] [Abstract][Full Text] [Related]
15. Chloroquine reverses chemoresistance via upregulation of p21 Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461 [TBL] [Abstract][Full Text] [Related]
16. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Rose FV; Barnea ER Oncogene; 1996 Mar; 12(5):999-1003. PubMed ID: 8649817 [TBL] [Abstract][Full Text] [Related]
17. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Scambia G; Della Bitta R; Benedetti Panici P; De Vincenzo R; Contu G; Ercoli A; Bonanno G; Pierelli L; Mancuso S Gynecol Oncol; 1995 Apr; 57(1):16-22. PubMed ID: 7705696 [TBL] [Abstract][Full Text] [Related]
18. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells. Futagami M; Sato S; Sakamoto T; Yokoyama Y; Saito Y Gynecol Oncol; 2001 Sep; 82(3):544-9. PubMed ID: 11520153 [TBL] [Abstract][Full Text] [Related]
19. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. Scambia G; Ranelletti FO; Benedetti Panici P; Bonanno G; De Vincenzo R; Piantelli M; Mancuso S Anticancer Drugs; 1990 Oct; 1(1):45-8. PubMed ID: 2131036 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]